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The relevance of aortic endograft prosthetic
infection
Paul Cernohorsky, MD,a Michel M.P.J. Reijnen, MD, PhD,b Ignace F. J. Tielliu, MD,a
Steven M. M. van Sterkenburg, MD,b Jan J.A.M. van den Dungen, MD, PhD,a and
Clark J. Zeebregts, MD, PhD,a Groningen and Arnheim, The Netherlands
Background: Vascular prosthetic graft infection is a severe complication after open aortic aneurysm repair. Reports of
infected endografts are scarce. General treatment consensus with infected graft material is that it should be removed
completely. The objective of this study was to describe the incidence of endograft infection after endovascular repair of
abdominal (EVAR) and thoracic aortic aneurysm (TEVAR) and to report treatment options and their outcome.
Methods: A retrospective cohort study was performed of patients endovascularly operated for abdominal and thoracic
aortic aneurysm in two large hospitals (one tertiary referral center and one large community hospital) between March
1996 and June 2009. Diagnosis of infected endograft was made based on clinical findings, blood tests and cultures,
imaging studies (computed tomography, fludeoxyglucose positron emission tomography), and intraoperative findings at
reoperation.
Results: Eleven patients with an infected endograft were identified in 1431 endovascular procedures. One other patient
was referred from another hospital. Patients were aged 68  9 years, and all but one were male. The median time from
initial TEVAR/EVAR to the diagnosis of infection was 115 days (range, 7-3748 days), with 42% of patients presenting
within 3 months after TEVAR/EVAR. Seven patients were diagnosed with endograft infection after elective TEVAR/
EVAR and five after emergency TEVAR/EVAR. The incidence was significantly higher in patients that were treated in
an emergency setting (0.56% vs 2.79%; P  .002), while there was no significant difference between TEVAR and EVAR
procedures (1.37% vs 0.77%). All patients were initially treated with antibiotic therapy, which was complemented with
surgical intervention in six patients. In four patients, the infected graft material was completely explanted. Isolated
microorganisms included Staphylococcus species (n  4), Streptococcus species (n  4), Enterobacter cloacae (n  1),
Escherichia coli (n  1), Pseudomonas aeruginosa (n  1), and Listeria monocytogenes (n  1). Median time of follow-up
was 201 days (range, 6-2023 days). During the study period, three out of 12 patients died, of which two were treated
conservatively (P  ns). At their last follow-up visit, seven of nine patients still used antimicrobial therapy.
Conclusions: The incidence of endograft infection is below 1%, with a mortality rate of 25%. Although consensus is that
infected graft material should always be removed, this study shows no significant difference in mortality between the
conservatively- and the surgically-managed group, possibly related to the small sample size. There may be a role for
conservative treatment in selected cases of patients with an infected endograft. ( J Vasc Surg 2011;54:327-33.)
g
a
F
i
O
m
g
p
w
c
o
s
e
d
r
o
c
p
c
dIn the last decade, endovascular aortic aneurysm repair
(EVAR) has evolved into a widely accepted treatment mo-
dality for aneurysms of both the abdominal (AAA) and
thoracic (TAA) aorta. Reported complications following
EVAR include endoleak, endograft migration, limb occlu-
sion, and rupture. Graft infection following EVAR has
scarcely been reported and so far appears to be confined to
single cases.1-8 The incidence of graft infection following
open aneurysm repair is reported to be between 0.4% and
3%.9,10 The minimal invasive character of EVAR may have
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doi:10.1016/j.jvs.2010.12.067iven rise to the hypothesis that endograft infection is
negligible complication that only very rarely occurs.
ollow-up protocols after EVAR, therefore, do usually not
nclude a screening strategy to detect endograft infection.
n the other hand, it may be anticipated that the high
orbidity and mortality rates, as described with infected
rafts after previous open repair,11 may also be applicable to
atients with aortic endografts in situ. General consensus
ith open surgery is that infected graft material should be
ompletely removed and replaced by autologous material
r reconstructed extra-anatomically,12 as conservative mea-
ures usually are associated with poor outcome.13 Also with
ndovascular repair, treatment with graft removal has been
escribed, as cases left untreated may even end up in
upture of the AAA.14,15 One case previously published by
ur group,3 however, suggests that there is also a place for
onservative treatment with endograft preservation as the
atient described is still alive and well after almost 4 years of
onservative treatment with antibiotics.
The aim of the present study was twofold; first, to
escribe the incidence of endograft infection after thoracic
ndovascular aneurysm repair (TEVAR) or EVAR in a large
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report treatment options and their outcome.
PATIENTS AND METHODS
Design of the study. A retrospective two-center co-
hort study was performed of all patients undergoing
TEVAR/EVAR between March 1996 and May 2009 in
two hospitals, the University Medical Center Groningen,
Groningen, The Netherlands (UMCG) and the Rijnstate
Hospital, Arnhem (RHA), The Netherlands, using institu-
tional databases. Information about initial TEVAR/EVAR
procedure, underlying disease, demographic aspects, diag-
nosis, treatment, and follow-up were all studied.
Definitions. Comorbidities were defined as recom-
mended by the Ad Hoc Committee on Reporting Stan-
dards.16 The diagnosis of graft infection was based on a
combination of criteria, including clinical findings such as
fever and pain, elevated infection parameters, evidence of
graft infection on computed tomography (CT) scan, mag-
netic resonance imaging, leukocytes scan, or 18fluorode-
oxyglucose positron emission tomography (FDG PET)
scan combined with CT-scan, operative findings (eg, ne-
crosis, purulent fluid, and infected graft material), and
isolation of microorganism from either blood, drain mate-
rial, or the endograft itself. On CT scan, a graft infection
was suspected if periprosthetic tissue infiltration and/or
fluid- or gas-filled collections were observed. On the FDG-
PET, focal pathological uptake was used as a diagnostic
criterion. Time to infection was defined as the window
between EVAR and the presentation of symptoms that led
to the diagnosis of endograft infection.
Follow-up protocol. During follow-up, diagnostic
investigations were focused on graft function and migra-
tion, endoleak, and structural abnormalities due to failing
material. Additionally, serum creatinine was measured ev-
ery 6 months to assess kidney function. There was, how-
ever, a difference in follow-up protocol between the treat-
ment hospitals.
In the UMCG series of patients treated with EVAR,
there have been two types of surveillance protocols. Before
1999, the Eurostar protocol was used, including computed
tomography angiography (CTA) at discharge, 1 month, 6
months, 1 year, and yearly thereafter. Also, ankle-brachial
index, plain abdominal x-ray and duplex ultrasound scan-
ning (DUS) were performed at the same intervals. From
1999, patients with an uncomplicated completion angiog-
raphy were discharged after plain abdominal x-ray only.
DUS was only performed in selected cases (ie, type II
endoleak at completion angiogram). Follow-up started
with CTA at 1 month, used as a reference for future
examinations. Thereafter, patients were followed with ab-
dominal x-ray and DUS at 6 months, 1 year, and yearly
thereafter.
For the RHA series, the Eurostar protocol was followed
until 1999. From then on, follow-up started with CTA at 6
weeks; thereafter, follow-up consisted of abdominal x-ray
and DUS every 6 months. Since 2009, the first CTA at 6
weeks has been replaced by abdominal x-ray and DUS. OTA was only performed when irregularities were found
uring standard follow-up in either one of the hospitals.
hese irregularities included the persistence of an endoleak,
rowth of the aneurysm sac, stenosis of a limb, and changes
n the position of the endograft. For the two TEVAR cases,
ime intervals of follow-up were similar as described above,
ut thoracic x-ray was performed instead of DUS and
bdominal x-ray.
Statistics. The data are presented as mean and stan-
ard deviation, unless indicated otherwise. P values .05
ere considered to be statistically significant. Differences
etween categorical variables were tested with Pearson
2 test. Statistical analysis was performed using the Sta-
istical Package for the Social Sciences (SPSS 16-0; SPSS,
hicago, Ill).
ESULTS
Subjects. BetweenMarch 1996 andMay 2009, a total
f 1431 EVAR and TEVAR procedures were performed in
he two hospitals combined. From these patients, 11 en-
ograft infections were identified. Two of them were
reated before by open AAA repair, which accounted for a
rue primary endograft infection rate of 0.63% of the study
opulation. Another patient with a suspected endograft
nfection was referred from another hospital for further
iagnosis, but was initially treated elsewhere. Patients were
ged 68 9 years, and all but one were male. Comorbidity
ncluded a cardiac history in seven patients, five were known
o have hypertension, and six had a history of chronic
bstructive pulmonary disease, of which none used corti-
osteroids as a standard prescription. Six patients were
mokers.
Two patients had been treated for aneurysmal dilata-
ion of the aorta prior to EVAR; in one case, this concerned
pen repair of a so-calledmycotic (ie, infected) aneurysm of
he abdominal aorta with autologous deep femoral vein,
nd the other patient was treated for a ruptured AAA for
hich open reconstruction with a Dacron prosthesis was
erformed.
Seven out of 12 patients were originally admitted for
lective TEVAR/EVAR (0.56% of total elective cases) and
ve for emergency TEVAR/EVAR (2.79% of total emer-
ency cases; P .002). Ten procedures were performed in
rder to exclude an AAA (0.77% of all AAAs) and two for a
AA (1.37% of all TAAs; P  .46). Ten were primary
rocedures, and two were redo-operations. All TEVAR/
VAR procedures were performed in operating theaters
ith laminar flow. Antibiotic prophylaxis was given to all
atients prior to surgery and included cefazolin 1000 mg
ntravenously in 10 cases and amoxicillin-clavulanic acid
200 mg intravenously in two cases. The implanted en-
ograft during initial TEVAR/EVAR involved a Talent
evice (Medtronic, Santa Rosa, Calif) in nine cases and a
ook Zenith device (Cook Inc, Bloomington, Ind) in three
ases.
Four patients underwent surgery between initial EVAR
nd the presentation of symptoms of endograft infection.
ne of these patients underwent stripping of the great
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tation of symptoms (Table I; patient no. 12). In another
patient, coil embolization for a type II endoleak and exten-
sion of a leg of the endograft was performed 5 months
before presentation of symptoms (Table I; patient no. 6).
The third patient underwent sigmoidal resection because of
diverticular disease 6 years before presentation of symp-
toms and 4 years following EVAR (Table I; patient no. 11).
The fourth patient presented with signs of infection 6
months after the implantation of a femorofemoral cross-
over bypass for an occluded leg of the endograft (Table I;
patient no. 5).
Time to infection. The median time from TEVAR/
EVAR to the diagnosis of infection was 115 days (range,
7-3748 days). Infection was diagnosed within 30 days after
TEVAR/EVAR in 25% of cases, within 3 months in 42%,
and within 1 year in 83%.
Diagnosis. The diagnosis of an endograft infection
was based on a combination of clinical symptoms and
imaging studies, supported by microbial cultures whenever
possible. Infection parameters were elevated in all patients
at time of diagnosis. Fever was present in eight patients,
malaise in three, and nine patients suffered from pain.
Other symptomatology included weight loss in two pa-
tients and cough, hemoptysis, dyspnea, nausea, vomiting,
Table I. Isolated microorganisms and treatment
Patient Microorganisms isolated
Origin cultured
M.O. Ant
1 Staphylococcus aureus Blood Piper
Staphylococcus epidermidis Drain/puncture
Pseudomonas aeruginosa Endograft
2 Streptococcus milleri Blood Benz
gen
Periaortic material/
endograft
3 None Amox
acid
4 Streptococcus viridans Blood Genta
am
Streptococcus constellatus
Staphylococcus aureus
5 Escherichia coli Blood Clind
Drain/puncture pip
taz
Endograft
6 Enterobacter cloacae Blood Metro
cef
Endograft
7 None Cipro
8 Streptococcus constellatus Blood Genta
9 None Amox
acid
10 Staphylococcus aureus Blood Fluclo
11 None Piper
12 Listeria monocytogenes Drain/puncture Amox
acid
trimand rectal blood loss all present in one patient. wA CT scan was performed in all cases (100%) to aid in
he diagnostic process, a FDG-PET in nine (75%), and a
eukocyte scan in three cases (25%). Blood samples were
ultured in 10 cases. In one case, this was complemented
obial therapy Treatment Outcome
Therapy at last
follow-up
/tazobactam Surgical Survived Ciprofloxacin 
minocydin
icillin 
cin
Surgical Survived Clindamycin 
co-trimoxazole
/clavulanic Surgical Survived Amoxicillin/clavulanic
acid 
metronidazole

lin
Surgical Survived None
in  Surgical Survived None
lin/
am
zole 
m
Surgical Died
cin Conservative Survived Ciprofloxacin
 penicillin Conservative Survived Co-trimoxazole
/clavulanic
entamicin
Conservative Died
lin Conservative Died
/tazobactam Conservative Survived Amoxicillin/clavulanic
acid
/clavulanic
o-
ole
Conservative Survived Co-trimoxazole
able II. Diagnostic tests performed during work-up of
uspected endograft infection
iagnostic tests N (%)
linical findings
Pain 9 (75)
Fever (T 37.5°C) 8 (67)
Elevated C-reactive protein (5 mg/L) 12 (100)
Elevated leukocyte count (10  10^9/L) 9 (75)
maging
Computed tomography 12 (100)
FDG-PET 9 (75)
Leukocyte scan 3 (25)
acterial cultures
Blood 10 (83)
Computed tomography-guided drainage 2 (17)
Wound drainage 1 (8)
DG-PET, Fludeoxyglucose positron emission tomography.imicr
acillin
ylpen
tami
icillin
micin
oxicil
amyc
eracil
obact
nida
uroxi
floxa
micin
icillin
 g
xacil
acillin
icillin
 cith cultures from drain fluid that was left in situ after
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August 2011330 Cernohorsky et alCT-guided puncture and, in another case, samples of drain
fluid from a wound drain were cultured. In one patient,
only a CT-guided puncture with subsequent drainage pro-
vided a culture, and in another patient, no cultures were
drawn. Table II shows an overview of used diagnostic tests
and their frequencies. Microorganisms were isolated in
eight out of 12 patients during the diagnostic process
and/or treatment. Table I lists the isolated microorgan-
isms, the combinations in which they were found, and the
subsequent antimicrobial therapy.
Staphylococcus aureus was the most frequently isolated
bacteria (n 3). During treatment for the infection or after
surgical intervention, additional microorganisms were iso-
lated in two of eight patients. In one of these two patients,
Staphylococcus epidermidis and Pseudomonas aeruginosa
were found intraoperatively, while in the other patient,
Streptococcus constellatus and Staphylococcus aureus were
found in blood cultures during the course of antimicrobial
therapy. In the four patients in which all bacterial cultures
remained negative, the diagnosis was based solely on clini-
cal findings and imagingmodalities (Table I; patient nos. 3,
7, 9, and 11). These cases presented with abnormalities on
CT scans and/or FDG-PET scans (eg, periaortic gas, fluid
collections, hot spots on FDG-PET; Fig 1). Combined
with clinical symptoms, the diagnosis of endograft infection
was most likely, and therefore they were treated as such.
Treatment. After the diagnosis of endograft infection
was made, one patient, diagnosed with low-grade infection
based on elevated laboratory infection parameters, periaor-
tic gas on CT, and a hot spot at the site of the prosthesis on
FDG-PET, was treated in the outpatient clinic with antibi-
otics. The remaining 11 patients were admitted for treat-
ment. In total, six patients were treated with antimicrobial
therapy only, guided by bacterial cultures whenever possi-
ble. Only one of these patients was unfit for surgery due to
Fig 1. Coronal (A) and sagittal (B) views of fused FDG
hot spot at the site of the overlap zone between body anhis pulmonary condition. The third column of Table I ehows the antimicrobial therapies given to the various
atients during admission. Patients in whom cultures
urned out negative were treated with broad-spectrum
ntibiotics.
In the other six patients, antimicrobial therapy was
ollowed by surgical intervention. In one of these cases,
ollowing TEVAR of a ruptured TAA for a suspected
nfected aneurysm, a secondary EVAR was performed with
he original endograft in situ, using a Gore Excluder device
W. L. Gore, Flagstaff, Ariz) to seal the proximal rupture.
ostoperatively, the patient was treated with intravenous
ntimicrobial therapy for 8 weeks, after which the patient
as discharged with oral antibiotic therapy (amoxicillin). In
nother patient, the operative risk for removal of the in-
ected endograft and open reconstruction was considered
oo high. It was decided to perform a laparotomy to rinse
he infected area. During the procedure, duodenal erosion
as found, which was oversewn and covered using an
mental flap. The patient was treated postoperatively with
enzylpenicillin and gentamicin intravenously.
In the remaining four patients, open reconstruction
ith removal of the endograft was performed. In one
ase, the abdominal aorta was reconstructed using an
ortobi-iliac silver-coated polyester prosthesis. In another
atient, who had previously undergone a femoral-femoral
rossover because of an occluded right leg of the endograft,
left-sided axillofemoral bypass was performed using a 6
m polyester prosthesis before the endograft was removed
uring subsequent laparotomy.17 During this procedure, it
as discovered that part of the small intestine adhered to
he right common iliac artery, uncovering a small defect
hen detached. The defect was closed, after which the
ndograft was completely removed. In another case, ex-
lantation of the endograft was followed by reconstruction
sing autologous deep femoral vein (Fig 2). In the last case,
-CT imaging of an infected aortic endograft. Clearly, a
ograft limbs is visible.-PETxplantation with subsequent reconstruction with com-
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hesis and a femorofemoral crossover bypass was per-
ormed.
Follow-up and outcome. All patients (n  1431)
ere followed-up after discharge. At 1 year, 15% (217/
431) of patients were lost to follow-up. From the remain-
ng cohort, 86% (1050/1214) were alive, and 14% (164/
214) had died. After 5 years, 23% (332/1431) were lost
o follow-up, and 433 patients did not yet reach 5-year
ollow-up because they had been treated within the past 5
ears. From the remaining cohort, 48% (323/666) were
live at 5-year follow-up, and 52% (343/666) had died.
ue to the low incidence of infected endografts, there was
o strict protocol for surveillance of infected endografts.
ollow-up is mainly based on the clinical performance of
he patient and preference of the treating physician. The
edian time of follow-up among the patients with en-
ograft infection was 201 days (range, 6-2023 days). The
atient with 6 days of follow-up only died at that time.
uring their last follow-up visit, seven of nine patients still
sed antimicrobial therapy (Table I). During the course of
reatment and follow-up, three of the 12 patients died
25%). Two of these patients were treated conservatively
ith antimicrobial therapy only, and one was treated with
pen surgery (P  ns).
One of the deceased patients presented with hypoten-
ion and increased heart rate 1 day after being discharged
ollowing primary EVAR. He was readmitted for antibiotic
reatment but deteriorated during the course of a week and
ied 6 days after readmission due to graft-related sepsis.
he second patient died 130 days after being admitted for
raft infection, 150 days after primary TEVAR. CT scan
howed a new aneurysmal dilatation of the thoracic aorta,
roximal of the endograft. A hot spot on FDG-PET scan
onfirmed the diagnosis of an infected endograft. The
atient was treated intravenously with amoxicillin/clavu-
anic acid and gentamicin, seemed to recover gradually, and
as discharged with oral antibiotic therapy (amoxicillin/
lavulanic acid). Eventually, the patient died of aorto-
ronchial fistula, which was found during autopsy.18 The
hird patient presented with pain and malaise, and the
DG-PET scan showed illumination of periaortic tissue.
T scan was repeated 1 week later and showed a leaking
neurysm. Emergency explantation with in situ reconstruc-
ion using an aortobi-iliac silver-coated polyester prosthesis
as performed, and the patient seemed to recover gradu-
lly. However, infection parameters remained elevated, and
he patient remained septic. The patient died 145 days after
riginal admission for endograft infection; no autopsy was
erformed.
ISCUSSION
In the present study, we have shown that the incidence
f endograft infection following TEVAR/EVAR is below
%. The observed incidence is in accordance with previous
stimations. Heyer et al reported incidences of prosthetic
nfection of 0.3% following EVAR and 4.8% followingFig 2. Intraoperative findings during reoperation after previous
polyester (tube) prosthesis and right aorto mono-iliac endograft
with femorofemoral crossover bypass.A, Completely disconnected
anastomoses of the polyester prosthesis from the aortic wall both at
proximal and distal ends (head of patient to the right). The
brownish area at the ventral side of the prosthesis indicated the
marks of an aortoduodenal fistula; blood flow was secured only by
the endograft. In the right upper corner, the suture line of duodenal
closure is depicted. B, Operation area after explantation of both
polyester prosthesis and endograft. Proximal aortic wall (on the
right) and wall of the right iliac artery (on the left) are marked by
tweezers. C, Intraoperative view after reconstruction with autolo-EVAR.19 Sharif et al noted an incidence of infection of
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August 2011332 Cernohorsky et al0.6%.20 Ducasse et al performed a retrospective multi-
center analysis that showed 0.4% infected endografts on a
total of 9739 endovascular treatments.21 In our series, 42%
of patients presented with signs of infection within 3
months after TEVAR/EVAR. In two of five patients pre-
senting with symptoms within 3 months after EVAR,
Staphylococcus aureus species were isolated. Staphylococcus
aureus is commonly present on the skin and has been
reported to be the most frequently isolated microorganism
in endograft infections.21 The short lag time to infection
emphasizes the role of prophylactic antibiotics during sur-
gery. Antibiotic prophylaxis in vascular surgery has been
proven beneficial to reduce surgical site infections after
reconstruction of the aorta, procedures on the leg that
involve a groin incision, any procedure that implants a
vascular prosthesis or endoluminal graft, and lower extrem-
ity amputation for ischemia.22,23 The given prophylactics in
this series were either cefazolin or amoxicillin/clavulanic
acid. Microorganisms isolated in patients who presented
with symptoms of infection within 3 months after
TEVAR/EVAR were all sensitive to the given prophylac-
tics. Additional surgical procedures may pose an increased
risk for infection of the inserted endograft.19 In this series,
four out of 12 patients underwent additional surgery fol-
lowing EVAR. Three of them underwent procedures that
are considered to be clean procedures, while the other
underwent colonic surgery. Unfortunately, the current
study group is too small to draw conclusions on the possible
indication, dosage, and duration of antibiotic prophylaxis
in patients following TEVAR/EVAR that need other
surgical procedures.
Due to extensive variation in presenting symptoms, it
may be difficult to diagnose the endograft infection. In this
series, the diagnosis was made based on several factors,
including clinical findings, cultures, and imaging studies. A
CT scan was performed in all cases to solidify the diagnosis;
FDG-PET was used in 75% of cases and proved a useful
diagnostic tool, especially in cases in which clinical findings
pointed toward infection, but no microorganisms were
isolated from cultures. Microorganisms were isolated in
eight out of 12 patients, which may raise the question
whether the diagnosis of endograft infection was appropri-
ate in the four other cases. Nevertheless, the combination
of other diagnostics provided sufficient evidence to support
the diagnosis of an infected endograft. All presented with
elevated infection parameters, while three of these four
patients had clinical complaints, including pain and fever.
CT scan showed abnormalities, such as periaortic gas and
fluid around the prostheses, and the FDG-PET scan
showed an increased uptake at the location of the prosthesis
in all four cases. The usefulness of an FDG-PET scan in the
diagnosis of a graft infection has been previously de-
scribed.24,25
Aortic endograft infection is associated with high mor-
bidity and mortality rates. Heyer et al reported a 30%
mortality in 10 cases with an infected endograft, with 75%
mortality in four (40%) conservatively treated patients.
Sharif et al reported a 50% mortality in six cases with an Onfected endograft, with 100% mortality in two (33%)
onservatively treated patients. Ducasse et al described 18%
ortality in 65 patients with endograft infection, with 36%
ortality in 11 (17%) conservatively treated patients. In our
eries, overall mortality was only 25% in 12 cases, with 33%
ortality in six (50%) conservatively treated patients. Gen-
ral consensus is that infected graft material should be
ompletely removed and that conservative treatment
hould be reserved for patients who are unfit to undergo
urgery. In this series, however, 50% of patients were
reated conservatively.
Furthermore, in only four of 12 cases was the infected
raft material completely removed. These observations
aise the question whether it is always necessary to remove
ll infected material and suggest that there could be room
or conservative treatment in selected cases, even if the
atient is fit enough for surgical intervention. On the other
and, it is more than likely that patients with worse infec-
ions were treated by graft excision and that those with
ore minor infections were treated with graft preservation,
endering any conclusions inconclusive. Adequate patient
election and monitoring of therapy might improve results
f conservatively-treated patients.
The retrospective design of our study has several draw-
acks. Due to the design, the decision-making process was
ot always very clear. A prospective registration on infected
ndografts may well give additional information consider-
ng the outcome of various treatment strategies. Due to the
ow incidence of graft infections, the power of our data may
e limited. The number of treated patients with an infected
ndograft was too small to draw any conclusions on actual
urvival rates. Moreover, the minor difference in incidence
etween EVAR and TEVAR did not reach statistical signif-
cance, due to the low number. However, this observation
s in accord with previous findings of Heyer et al.19
ONCLUSIONS
In conclusion, endograft infection is a rare complica-
ion after TEVAR/EVAR associated with high mortality
ate. A large percentage of cases present with symptoms
ithin 3 months after TEVAR/EVAR (42%), and the
ncidence is significantly higher following emergency
EVAR/EVAR. In our series, there was no significant
ifference in survival between surgically and conservatively
reated patients, possibly related to the small sample size.
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